<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Biomedical Journal</title>
<title_fa>مجله بیومدیکال ایران</title_fa>
<short_title>IBJ</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ibj.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>1028-852X</journal_id_issn>
<journal_id_issn_online>2008-823X</journal_id_issn_online>
<journal_id_pii>-</journal_id_pii>
<journal_id_doi>10.61882/ibj</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>-</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>-</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1403</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2024</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<volume>28</volume>
<number>7</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Development and Evaluation of Fexofenadine Dry Powder Inhalation</title>
	<subject_fa></subject_fa>
	<subject></subject>
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-family:Times New Roman;&quot;&gt;&lt;span style=&quot;font-size:14px;&quot;&gt;&lt;span style=&quot;line-height:normal&quot;&gt;&lt;b&gt;&lt;span style=&quot;color:black&quot;&gt;Introduction: &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;color:black&quot;&gt;The aim of this study was to develop and evaluate nano-fexofenadine dry powder inhaler (DPI) and to characterize the physicochemical and aerodynamic properties.&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;line-height:normal&quot;&gt;&lt;b&gt;&lt;span style=&quot;color:black&quot;&gt;Methods and Materials: &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;color:black&quot;&gt;Various excipients were employed to prepare suspensions of nanoparticles of fexofenadine, comprising ethanol, water, sodium lauryl sulfate, and Tween 80, using the antisolvent method. The DPI was formulated using the spray freeze-drying method, incorporating nanosuspension along with matrix formers such as mannitol, sorbitol, lactose, sucrose, maltodextrin, and PEG 400. The prepared DPI formulations were characterized using scanning electron microscopy, &lt;/span&gt;Fourier-transform infrared spectroscopy&lt;span style=&quot;color:black&quot;&gt;, differential scanning calorimetry, bulk and tapped density measurments, DLS, and dissolution tests. The &lt;/span&gt;aerosolization&lt;span style=&quot;color:black&quot;&gt; properties of the different formulations were evaluated using a twin impinger impactor, and the percentage of &lt;/span&gt;fine particle fraction (&lt;span style=&quot;color:black&quot;&gt;FPF) was determined. &lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;span style=&quot;line-height:normal&quot;&gt;&lt;b&gt;&lt;span style=&quot;color:black&quot;&gt;Results: &lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;color:black&quot;&gt;The results showed that the inclusion of matrix formers in the formulations enhanced the dissolution behavior of fexofenadine. The needle-shaped particle morphology of the spray freeze-dried nanoparticles containing mannitol was observed. These nanoparticles exhibited low density and extremely poor flowability properties (%CI&lt;sub&gt;40&lt;/sub&gt;), yet they resulted in the highest percentage of FPF (27.91%).&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&lt;b&gt;&lt;span style=&quot;line-height:107%&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;Conclusion and Discussion:&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;span style=&quot;line-height:107%&quot;&gt;&lt;span style=&quot;color:black&quot;&gt; DPI, as a route of drug administration, may offer several advantages, including ease of use, a high rate of bioavailability, and a reduction of systemic side effects.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;br&gt;
&lt;span style=&quot;font-family:Times New Roman;&quot;&gt;&lt;img alt=&quot;&quot; src=&quot;./files/site1/images/888.jpg&quot; style=&quot;width: 1000px; height: 36px;&quot; &gt;&lt;/span&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword></keyword>
	<start_page>144</start_page>
	<end_page>144</end_page>
	<web_url>http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-4696-149&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Samira </first_name>
	<middle_name></middle_name>
	<last_name>Simbor</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Ali Mohammad </first_name>
	<middle_name></middle_name>
	<last_name>Ranjbar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Amirreza</first_name>
	<middle_name></middle_name>
	<last_name>Torabi Mirzaei</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Vahid </first_name>
	<middle_name></middle_name>
	<last_name>Ramezani</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation></affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
